Understanding Apparent Mineralocorticoid Excess
At a Glance
Apparent mineralocorticoid excess (AME) is a rare disorder in which cortisol acts like aldosterone in the kidneys, causing salt and water retention, potassium loss, and severe high blood pressure. Doctors distinguish inherited AME from triggers such as real licorice or posaconazole.
Receiving a diagnosis of Apparent Mineralocorticoid Excess (AME) for you or your child can feel like being handed a map to a place no one has ever heard of. It is natural to feel a sense of isolation or confusion when even your local pediatrician might be reaching for a medical textbook to understand it. Because AME is incredibly rare, you are likely the first person in your community—and perhaps the first in your doctor’s career—to face this challenge [1][2].
How Rare is AME?
AME is truly “ultra-rare.” While many rare diseases affect one in a few thousand people, classic AME is estimated to affect only about 0.6 to 6.8 people for every 10 million [3]. While historical literature cites fewer than 100 documented cases, it is likely underdiagnosed.
Because it is so uncommon, it is completely normal for a primary care doctor to have never seen a case. Most doctors only encounter AME as a single paragraph in a medical school textbook. This is why your care will likely transition to a specialist, such as a nephrologist (kidney specialist) or an endocrinologist (hormone specialist), who has the specific tools to manage this condition.
What is Happening in the Body?
To understand AME, it helps to think of the kidney as having a “security guard” for its hormone receptors. Usually, a hormone called aldosterone is the only one supposed to turn on the kidney’s “salt-saving” switch. Another hormone, cortisol (your body’s stress hormone), is also capable of turning on this switch, but it is normally blocked from doing so [4][5].
The body uses an enzyme called 11β-HSD2 to act as this security guard. It catches cortisol and turns it into an inactive form called cortisone before it can touch the salt-saving switch [6][5]. In AME, this security guard is either missing or not working. As a result, the kidney’s receptors are stimulated by cortisol. The kidney “thinks” the body is starving for salt and begins to hold onto sodium and water while dumping potassium [7][8]. This leads to the classic signs of AME: severe high blood pressure and low potassium levels.
Genetic (Classic) vs. Acquired AME
There are two ways someone might develop AME: they were born with it (genetic), or they were exposed to something that stopped their “security guard” enzyme from working (acquired).
Classic AME (Genetic)
Classic AME is a genetic condition caused by mutations in the HSD11B2 gene [7].
- Inheritance: It follows an autosomal recessive pattern. This means for a person to have the condition, they must inherit one changed gene from each parent [9][10].
- Carrier Status: Parents are typically “carriers,” meaning they have one healthy gene and one changed gene. Carriers usually have no symptoms and no high blood pressure [7][10].
- Presentation: This form usually appears very early in childhood, often involving poor growth (failure to thrive) and excessive thirst or urination [11][12]. Milder forms can sometimes present in adulthood.
Acquired AME
In some cases, a person might have a working gene but something in their environment chemically “turns off” the 11β-HSD2 enzyme.
- Licorice: The most common cause of acquired AME is consuming large amounts of real licorice (specifically glycyrrhizic acid). This substance chemically disables the security guard enzyme, mimicking the genetic disease [13][14]. Note that many “licorice” flavored candies in the U.S. use anise oil and do not contain real glycyrrhizic acid.
- Medications: Certain medications, particularly the antifungal drug posaconazole, have been found to inhibit this same enzyme or related pathways, leading to temporary AME-like symptoms [15][16]. Important: Never stop a prescribed medication on your own; if you suspect it is causing high blood pressure, consult your prescriber promptly.
Why Diagnosis Takes Time
Because AME is so rare, doctors usually look for more common causes of high blood pressure first. A diagnosis of AME is often suspected only after blood tests show a “low-renin, low-aldosterone” pattern—meaning the body has shut down its normal salt-regulating hormones because it already feels overloaded [11][17].
To investigate further, specialists look at the urinary cortisol-to-cortisone metabolite ratio. In a healthy person, there is much more cortisone metabolite than cortisol metabolite in the urine. In AME, the ratio is abnormal because the conversion process is broken [18][12]. Genetic testing is then used to find the specific mutation in the HSD11B2 gene to confirm the classic form of the disease [9][19].
While the journey to a diagnosis can be overwhelming, identifying the specific type of AME—whether genetic or acquired—is the first step in creating a targeted plan to protect the kidneys and heart.
Common questions in this guide
What is apparent mineralocorticoid excess, and what does it do?
What causes inherited and acquired AME?
How is AME diagnosed?
What signs might suggest AME in a child?
Does AME run in families?
Can licorice or medication trigger AME-like symptoms?
What kidney and heart problems might doctors check for in AME?
Get notified when new evidence is published on Apparent mineralocorticoid excess.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
Novel homozygous pathogenic variant in HSD11B2 as a cause of apparent mineralocorticoid excess.
Roche-Gomez A, Blázquez Gómez CJ, Licero Villanueva A, Espino Hernández M
Journal of hypertension 2025; (43(12)):2072-2074 doi:10.1097/HJH.0000000000004159.
PMID: 41039756 - 2
Facial nerve palsy and hypertension; unusual presentation of apparent mineralocorticoid excess (AME) syndrome in a paediatric patient.
Jawed S, Daffue B, Riordan M, Enright F
BMJ case reports 2026; (19(10)) doi:10.1136/bcr-2026-273050.
PMID: 42843912 - 3
Population-based estimates of the global prevalence and carrier frequency of apparent mineralocorticoid excess caused by 11β-hydroxysteroid dehydrogenase type 2 deficiency.
Charoenngam N, Kansuttiviwat C, Chinsawangwatanakul P
Orphanet journal of rare diseases 2025; (21(1)):1 doi:10.1186/s13023-025-04160-x.
PMID: 41316338 - 4
Alterations of Cortisol Metabolism in Human Disorders.
White PC
Hormone research in paediatrics 2018; (89(5)):320-330 doi:10.1159/000485508.
PMID: 29843121 - 5
In vitro methods to assess 11β-hydroxysteroid dehydrogenase type 2 activity.
Kley M, Moser SO, Winter DV, Odermatt A
Methods in enzymology 2023; (689()):167-200 doi:10.1016/bs.mie.2023.04.005.
PMID: 37802570 - 6
The Dehydrogenase Hypothesis.
Woods C, Tomlinson JW
Advances in experimental medicine and biology 2015; (872()):353-80 doi:10.1007/978-1-4939-2895-8_16.
PMID: 26216003 - 7
Apparent mineralocorticoid excess: comprehensive overview of molecular genetics.
Lu YT, Zhang D, Zhang QY, et al.
Journal of translational medicine 2022; (20(1)):500 doi:10.1186/s12967-022-03698-9.
PMID: 36329487 - 8
Renal Dysfunction Induced by Kidney-Specific Gene Deletion of Hsd11b2 as a Primary Cause of Salt-Dependent Hypertension.
Ueda K, Nishimoto M, Hirohama D, et al.
Hypertension (Dallas, Tex. : 1979) 2017; (70(1)):111-118 doi:10.1161/HYPERTENSIONAHA.116.08966.
PMID: 28559392 - 9
Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia.
Fan P, Lu YT, Yang KQ, et al.
Endocrine 2020; (70(3)):607-615 doi:10.1007/s12020-020-02460-9.
PMID: 32816205 - 10
Apparent Mineralocorticoid Excess by a Novel Mutation and Epigenetic Modulation by HSD11B2 Promoter Methylation.
Pizzolo F, Friso S, Morandini F, et al.
The Journal of clinical endocrinology and metabolism 2015; (100(9)):E1234-41 doi:10.1210/jc.2015-1760.
PMID: 26126204 - 11
Apparent mineralocorticoid excess mimicking Bartter syndrome in infancy.
Hatipoğlu S, Yıldırım E, Şalbaş ÖY, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2026; doi:10.1515/jpem-2026-0333.
PMID: 42912472 - 12
Apparent Mineralocorticoid Excess in the Pediatric Population: Report of a Novel Pathogenic Variant of the 11β-HSD2 Gene and Systematic Review of the Literature.
Adamidis A, Cantas-Orsdemir S, Tsirka A, et al.
Pediatric endocrinology reviews : PER 2019; (16(3)):335-358 doi:10.17458/per.vol16.2019.act.mineralocorticoid.
PMID: 30888125 - 13
[Adverse effects of licorice consumed as food: An update].
Caré W, Grenet G, Schmitt C, et al.
La Revue de medecine interne 2023; (44(9)):487-494 doi:10.1016/j.revmed.2023.03.004.
PMID: 37005098 - 14
Bioactive Candy: Effects of Licorice on the Cardiovascular System.
Deutch MR, Grimm D, Wehland M, et al.
Foods (Basel, Switzerland) 2019; (8(10)) doi:10.3390/foods8100495.
PMID: 31615045 - 15
Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2.
Thompson GR, Beck KR, Patt M, et al.
Journal of the Endocrine Society 2019; (3(7)):1361-1366 doi:10.1210/js.2019-00189.
PMID: 31286100 - 16
Mineralocorticoid hypertension and hypokalaemia induced by posaconazole.
Boughton C, Taylor D, Ghataore L, et al.
Endocrinology, diabetes & metabolism case reports 2018; (2018()) doi:10.1530/EDM-17-0157.
PMID: 29472988 - 17
Species-specific differences in the inhibition of 11β-hydroxysteroid dehydrogenase 2 by itraconazole and posaconazole.
Inderbinen SG, Zogg M, Kley M, et al.
Toxicology and applied pharmacology 2021; (412()):115387 doi:10.1016/j.taap.2020.115387.
PMID: 33387577 - 18
Apparent mineralocorticoid excess.
Funder JW
The Journal of steroid biochemistry and molecular biology 2017; (165(Pt A)):151-153 doi:10.1016/j.jsbmb.2016.03.010.
PMID: 26956190 - 19
Apparent mineralocorticoid excess with a novel HSD11B2 variant: longitudinal clinical and biochemical follow-Up.
Nalluri BT, Kudugunti N, Sahay RK
JCEM case reports 2026; (4(6)):luag083 doi:10.1210/jcemcr/luag083.
PMID: 42064719
This page is for informational purposes only and does not constitute medical advice. A nephrologist or endocrinologist should interpret your or your child’s tests and guide care for apparent mineralocorticoid excess.